Table 2.
Impact of disclosure on elevated viral load (VL, in copies/mL) at entry into antenatal care among women already on antiretroviral therapy (ART)
| Variable | Total sample – n (%) | VL <50 – n (%) | VL ≥50 – n (%) | OR [95% CI]1 | P-value | aOR [95% CI]2 | P-value |
|---|---|---|---|---|---|---|---|
| Number of women | 559 | 439 | 120 | ||||
| Male partner disclosure | |||||||
| Has not disclosed | 83 (15) | 63 (14) | 20 (17) | Reference | Reference | ||
| Has disclosed | 476 (85) | 376 (86) | 100 (83) | 0.84 [0.48, 1.45] | 0.528 | 0.84 [0.48, 1.49] | 0.558 |
| Family/community disclosure | |||||||
| Disclosed to none | 30 (5) | 24 (5) | 6 (5) | Reference | Reference | ||
| Disclosed to ≥1 person | 529 (95) | 415 (95) | 114 (95) | 1.10 [0.44, 2.75] | 0.841 | 0.90 [0.35, 2.33] | 0.827 |
1
OR: odds ratio
2
aOR: adjusted odds ratio; adjusted for age, poverty, relationship status, time since HIV diagnosis.